Shambhu G Aralaguppe1, Dane Winner2, Kamalendra Singh3, Stefan G Sarafianos3, Miguel E Quiñones-Mateu2,4, Anders Sönnerborg1,5, Ujjwal Neogi6. 1. Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden. 2. University Hospital Translational Laboratory, University Hospitals Case Medical Center, Cleveland, Ohio. 3. Department of Molecular Microbiology and Immunology, Christopher Bond Life Sciences Center, University of Missouri, Columbia, Missouri. 4. Department of Pathology, Case Western Reserve University, Cleveland, Ohio. 5. Unit of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden. 6. Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden. ujjwal.neogi@ki.se.
Abstract
BACKGROUND: A lower virulence of HIV-1 subtype C (HIV-1C) is suggested to be related to the global dominance of HIV-1C. In this observational study, combining in vivo (clinical monitoring) and in vitro (genotypic, biochemical, and phenotypic assays), we explored whether HIV-1C from East Africa (HIV-1CEA ) is more pathogenic due to the evolution of a PYxE-insertion (CPYxEi ) in the gag-p6 that also could affect the therapy response. METHODS: HIV-1B (n = 112) and HIV-1CEA (n = 128)-infected individuals residing in Sweden were analyzed with regard to Gag-p6 genotype and clinically monitored. Based on the Gag-p6 characteristics, three HIV-1CEA and one HIV-1 B patient-derived p2-INT-recombinant virus (gag-p2/NCp7/p1/p6/pol-PR/RT/IN) were constructed to analyze viral growth kinetics (VGKs) and drug sensitivity assays. Reverse transcriptase (RT) from the same samples was cloned into the heterodimer expression plasmid (pRT6H-PROT) to analyze catalytic efficiency of RT. RESULTS: A higher viral failure rate and lower pre-therapy CD4+ T-cell counts were observed in HIV-1CEA -infected patients compared to HIV-1B-infected patients. In Gag-p6, PTAP-duplication was more common in HIV-1C. HIV-1CEA -infected patients with signature CPYxEi, evidenced very low pre-therapy CD4+ T-cell counts and suboptimal gain in CD4+ T-cells following therapy, as compared to the non-CPYxEi -strains indicating higher virulence. VGKs showed a statistically significant higher replication capacity (RC) for the CPYxEi viruses than the other two non-CPYxEi strains. No statistically significant difference was observed in the catalytic efficiency among HIV-1C RTs. CONCLUSIONS: This is the first evidence of polymerase independent increased virulence and RC in HIV-1CEA following PYxE-insertion that is associated with suboptimal CD4+ T-cell gain following therapy initiation. J. Med. Virol. 89:106-111, 2017.
BACKGROUND: A lower virulence of HIV-1 subtype C (HIV-1C) is suggested to be related to the global dominance of HIV-1C. In this observational study, combining in vivo (clinical monitoring) and in vitro (genotypic, biochemical, and phenotypic assays), we explored whether HIV-1C from East Africa (HIV-1CEA ) is more pathogenic due to the evolution of a PYxE-insertion (CPYxEi ) in the gag-p6 that also could affect the therapy response. METHODS:HIV-1B (n = 112) and HIV-1CEA (n = 128)-infected individuals residing in Sweden were analyzed with regard to Gag-p6 genotype and clinically monitored. Based on the Gag-p6 characteristics, three HIV-1CEA and one HIV-1 B patient-derived p2-INT-recombinant virus (gag-p2/NCp7/p1/p6/pol-PR/RT/IN) were constructed to analyze viral growth kinetics (VGKs) and drug sensitivity assays. Reverse transcriptase (RT) from the same samples was cloned into the heterodimer expression plasmid (pRT6H-PROT) to analyze catalytic efficiency of RT. RESULTS: A higher viral failure rate and lower pre-therapy CD4+ T-cell counts were observed in HIV-1CEA -infectedpatients compared to HIV-1B-infectedpatients. In Gag-p6, PTAP-duplication was more common in HIV-1C. HIV-1CEA -infectedpatients with signature CPYxEi, evidenced very low pre-therapy CD4+ T-cell counts and suboptimal gain in CD4+ T-cells following therapy, as compared to the non-CPYxEi -strains indicating higher virulence. VGKs showed a statistically significant higher replication capacity (RC) for the CPYxEi viruses than the other two non-CPYxEi strains. No statistically significant difference was observed in the catalytic efficiency among HIV-1C RTs. CONCLUSIONS: This is the first evidence of polymerase independent increased virulence and RC in HIV-1CEA following PYxE-insertion that is associated with suboptimal CD4+ T-cell gain following therapy initiation. J. Med. Virol. 89:106-111, 2017.
Authors: David O Ajasin; Vasudev R Rao; Xuhong Wu; Santhamani Ramasamy; Mario Pujato; Arthur P Ruiz; Andras Fiser; Anne R Bresnick; Ganjam V Kalpana; Vinayaka R Prasad Journal: Elife Date: 2019-06-07 Impact factor: 8.140
Authors: Marion W Kiguoya; Jaclyn K Mann; Denis Chopera; Kamini Gounder; Guinevere Q Lee; Peter W Hunt; Jeffrey N Martin; T Blake Ball; Joshua Kimani; Zabrina L Brumme; Mark A Brockman; Thumbi Ndung'u Journal: J Virol Date: 2017-06-09 Impact factor: 5.103
Authors: Asa Rahimi; Gursev Anmole; Maribel Soto-Nava; Tania Escamilla-Gomez; Tristan Markle; Steven W Jin; Guinevere Q Lee; P Richard Harrigan; David R Bangsberg; Jeffrey Martin; Santiago Avila-Rios; Gustavo Reyes-Teran; Mark A Brockman; Zabrina L Brumme Journal: J Virol Methods Date: 2016-11-16 Impact factor: 2.014
Authors: Anne Kapaata; Sheila N Balinda; Rui Xu; Maria G Salazar; Kimberly Herard; Kelsie Brooks; Kato Laban; Jonathan Hare; Dario Dilernia; Anatoli Kamali; Eugene Ruzagira; Freddie Mukasa; Jill Gilmour; Jesus F Salazar-Gonzalez; Ling Yue; Matthew Cotten; Eric Hunter; Pontiano Kaleebu Journal: Viruses Date: 2021-01-23 Impact factor: 5.048
Authors: Zabrina L Brumme; Mark A Brockman; Gisele Umviligihozo; Kyle D Cobarrubias; Sandali Chandrarathna; Steven W Jin; Nicole Reddy; Helen Byakwaga; Conrad Muzoora; Mwebesa B Bwana; Guinevere Q Lee; Peter W Hunt; Jeff N Martin; Chanson J Brumme; David R Bangsberg; Etienne Karita; Susan Allen; Eric Hunter; Thumbi Ndung'u Journal: J Virol Date: 2020-07-01 Impact factor: 5.103